Sunitinib in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00514228|
Recruitment Status : Completed
First Posted : August 9, 2007
Last Update Posted : June 26, 2012
RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
PURPOSE: This phase II trial is studying how well sunitinib works in treating patients with liver cancer that cannot be removed by surgery.
|Condition or disease||Intervention/treatment||Phase|
|Liver Cancer||Drug: sunitinib malate||Phase 2|
- Demonstrate the antitumor activity of continuous sunitinib malate treatment in patients with unresectable hepatocellular carcinoma.
- Evaluate the safety of sunitinib malate treatment.
- Measure serum cobalamin (i.e., vitamin B12) level during sunitinib malate treatment in order to investigate the relationship between sunitinib malate treatment and cobalamin deficiency.
- Control the cobalamin deficiency by cobalamin replacement.
- Investigate whether changes in tumor density could be used as a criterion for tumor response in future trials.
OUTLINE: This is a multicenter study.
Patients receive oral sunitinib malate once daily. Treatment continues in the absence of disease progression or unacceptable toxicity.
Patients undergo blood sample collection on day 1 of each course to assess serum cobalamin levels and correlation with sunitinib malate treatment. Patients are also assessed for changes in tumor density and correlation with response. Baseline CT scans are compared with scans performed at 6 and 12 weeks to evaluate changes in CT-scan density due to tumor necrosis and response.
After completion of study therapy, patients are followed at least every 3 months for up to 3 years.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||45 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Continuous Sunitinib Treatment in Patients With Unresectable Hepatocellular Carcinoma A Multicenter Phase II Trial|
|Study Start Date :||July 2007|
|Actual Primary Completion Date :||August 2008|
|Actual Study Completion Date :||February 2009|
|Experimental: Continuous sunitinib treatment||
Drug: sunitinib malate
Other Name: Sutent
- Progression-free survival [ Time Frame: at 12 weeks ]
- Objective response [ Time Frame: Objective response (CR+PR) to treatment will be determined. CR or PR is to be confirmed after a minimum of 4 weeks ]
- Disease stabilization (DS) [ Time Frame: Disease stabilization (CR, PR or SD) under sunitinib treatment will be determined ]
- Duration of DS [ Time Frame: Duration of DS (CR, PR or SD) will be calculated from the time that measurement criteria are met for the first time until documented tumor progression ]
- Progression-free survival [ Time Frame: PFS will be calculated from registration until documented tumor progression or death, whichever occurs first. ]
- Time to progression [ Time Frame: TTP will be calculated from registration until documented tumor progression or death due to tumor. ]
- Overall survival [ Time Frame: OS will be calculated from registration until death ]
- Adverse events as assessed by NCI CTCAE v3.0 [ Time Frame: All AEs will be assessed according to NCI CTCAE v3.0. ]
- Serum alpha fetoprotein level [ Time Frame: Serum AFP levels will be measured during the therapy, if AFP is ≥ 1.5 x ULN at baseline. ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00514228
|Kantonsspital - St. Gallen|
|St. Gallen, Switzerland, CH-9007|
|Study Chair:||Dieter Koeberle, MD||Cantonal Hospital of St. Gallen|